1. Scrip
  2. >>R&D
  3. >>Clinical Trials

NGM Phase IIb NASH Failure Could Darken Competitors’ Prospects

 
• By Joseph Haas

NGM will not proceed with a Phase III study in F2/F3 NASH following failure to show fibrosis benefit in Phase IIb. Analysts say this setback could portend disappointing readouts for other NASH players.

Business strategy failure as a despair metaphor or financial market drop and psychological burnout symbol in a 3D illustration style.
NGM hopes investors will be enthused about its pipeline as it moves away from NASH

NGM Biopharmaceuticals, Inc. missed the primary endpoint in a Phase IIb study intended to show a reduction in fibrosis in non-alcoholic steatohepatitis patients with mid-stage fibrosis (F2/F3) scores, a result both the company and analysts called surprising based on earlier datasets for aldafermin. The daily injectable FGF19 analog had showed ability to reduce fibrosis in NASH patients in a biopsy-based Phase II study while also showing numerous potential liver health benefits measured by non-invasive tests.

During a 24 May investor call to overview the topline ALPINE 2/3 data, NGM CEO David Woodhouse said his company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By Vibha Ravi

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers